<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Naunyn Schmiedebergs Arch Pharmacol</journal-id>
      <journal-title>Naunyn-Schmiedeberg's Archives of Pharmacology</journal-title>
      <issn pub-type="ppub">0028-1298</issn>
      <issn pub-type="epub">1432-1912</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18398599</article-id>
      <article-id pub-id-type="pmc">2323035</article-id>
      <article-id pub-id-type="publisher-id">280</article-id>
      <article-id pub-id-type="doi">10.1007/s00210-008-0280-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Michel</surname>
            <given-names>Martin C.</given-names>
          </name>
          <address>
            <phone>+31-20-5666762</phone>
            <fax>+31-20-6965976</fax>
            <email>m.c.michel@amc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fliers</surname>
            <given-names>Eric</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Van Noorden</surname>
            <given-names>Cornelis J. F.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pharmacology and Pharmacotherapy, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands </aff>
        <aff id="Aff3"><label>3</label>Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>4</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2008</year>
      </pub-date>
      <volume>377</volume>
      <issue>3</issue>
      <fpage>205</fpage>
      <lpage>207</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2008</copyright-statement>
      </permissions>
      <abstract>
        <p>Inhibitors of the protease dipeptidyl peptidase IV (DPP-IV) are promising new drugs for the treatment of type 2 diabetes. They are thought to act by inhibiting the breakdown of glucagon-like peptide-1 and, thereby, selectively enhancing insulin release under conditions when it is physiologically required. These drugs are selective for DPP-IV, but the enzyme itself has a broad range of substrates other than glucagon-like peptide-1. Other high affinity substrates of DPP-IV including peptide YY may also play a role in the regulation of energy homeostasis. Moreover, DPP-IV is also known as CD26 and considered to be a moonlighting protein because it has a wide range of other functions unrelated to energy homeostasis, e.g. in immunity. The potential role of DPP-IV inhibition on substrates other than glucagon-like peptide-1 in diabetes patients remains to be elucidated.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Dipeptidyl peptidase IV</kwd>
        <kwd>Glucagon-like peptide-1</kwd>
        <kwd>Peptide YY</kwd>
        <kwd>Diabetes</kwd>
        <kwd>CD26</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <p>Glucagon-like peptide-1 (GLP-1) is a hormone which is released following meals and stimulates insulin release from the pancreas. Its effects are terminated by breakdown by the enzyme dipeptidyl peptidase IV (DPP-IV). Therefore, inhibition of DPP-IV increases GLP-1 levels in the circulation and, hence, insulin release under conditions when it is needed, i.e. after a meal but not during fasting. Consequently, inhibition of GLP-1 inactivation is an insulinotropic principle which is unlikely to cause hypoglycaemia between meals. The lower risk for hypoglycaemic events as compared with other insulinotropic or insulin-sensitising agents makes DPP-IV inhibitors very promising candidates for a more physiological treatment of type 2 diabetes (Combettes and Kargar <xref ref-type="bibr" rid="CR5">2008</xref>).</p>
    <p>In recent years, a number of selective DPP-IV inhibitors such as vildagliptin and sitagliptin have been evaluated in clinical trials (Hermansen et al. <xref ref-type="bibr" rid="CR7">2007</xref>; Utzschneider et al. <xref ref-type="bibr" rid="CR22">2008</xref>) and may have a future role in the treatment of type 2 diabetes (Combettes and Kargar <xref ref-type="bibr" rid="CR5">2008</xref>). In this issue of the journal, a novel DPP-IV inhibitor, ASP8497, is being introduced, which is highly selective for DPP-IV as compared to other peptidases (Someya et al. <xref ref-type="bibr" rid="CR19">2008</xref>). However, DPP-IV itself is not selective for GLP-1 but has a wide range of other natural substrates (Boonacker and Van Noorden <xref ref-type="bibr" rid="CR4">2003</xref>). Therefore, we wish to highlight potential implications of this lack of selectivity of DPP-IV for the use of DPP-IV inhibitors in diabetes treatment.</p>
    <p>Another high affinity substrate of DPP-IV is peptide YY (PYY; Mentlein et al. <xref ref-type="bibr" rid="CR11">1993</xref>). Whereas cleavage of GLP-1 by DPP-IV causes inactivation, cleavage of PYY yields the long C-terminal fragment PYY<sub>3&#x2013;36</sub>, which is inactive at some but active at other subtypes of PYY receptors. Specifically, it converts the non-subtype-selective agonist PYY into a selective agonist at Y<sub>2</sub> and Y<sub>5</sub> receptors (Michel et al. <xref ref-type="bibr" rid="CR12">1998</xref>). Thus, DPP-IV does not inactivate PYY but, rather, qualitatively alters its biological activity.</p>
    <p>Indeed it has been reported that peripherally administered PYY<sub>3&#x2013;36</sub> inhibits food intake in rats, whereas PYY is a potent central stimulator of food intake (Batterham et al. <xref ref-type="bibr" rid="CR1">2002</xref>). Given the role of obesity in type 2 diabetes, prevention of the formation of such an endogenous food intake inhibitor by a DPP-IV inhibitor may be undesirable. It has been proposed that the effects of peripherally administered PYY<sub>3&#x2013;36</sub> on central nervous functions such as food intake may be mediated by excitation of afferent vagal fibres (Koda et al. <xref ref-type="bibr" rid="CR10">2005</xref>). However, the majority of subsequent rodent studies did not confirm inhibition of food intake by PYY<sub>3&#x2013;36</sub>, particularly not following chronic administration (Boggiano et al. <xref ref-type="bibr" rid="CR3">2005</xref>). On the other hand, recent studies in non-rodents such as pigs (Ito et al. <xref ref-type="bibr" rid="CR8">2006</xref>) or humans (Degen et al. <xref ref-type="bibr" rid="CR6">2005</xref>; Sloth et al. <xref ref-type="bibr" rid="CR17">2007a</xref>; Sloth et al. <xref ref-type="bibr" rid="CR18">2007b</xref>) have reported reduced food intake upon peripheral administration of PYY<sub>3&#x2013;36</sub> but typically, these effects were found only at relatively high concentrations. Moreover, the effect of PYY<sub>3&#x2013;36</sub> on food intake was biphasic, depending on the duration of its administration (Parkinson et al. <xref ref-type="bibr" rid="CR14">2008</xref>). Two additional findings deserve consideration. Firstly, PYY<sub>3&#x2013;36</sub> was reported to promote fat oxidation and ameliorate insulin resistance in mice even under conditions of chronic administration where it did not reduce food intake (van den Hoek et al. <xref ref-type="bibr" rid="CR23">2006</xref>). Secondly, PYY<sub>3&#x2013;36</sub> was reported to lower plasma glucose levels even in the absence of alterations in circulating insulin levels (Bischoff and Michel <xref ref-type="bibr" rid="CR2">1998</xref>).</p>
    <p>Taken together, the presently available data on PYY<sub>3&#x2013;36</sub> on food intake and metabolic parameters are not yet conclusive. However, it is clear that PYY<sub>3&#x2013;36</sub> is largely formed by DPP-IV, raising the possibility that selective DPP-IV inhibitors may exert part of their effects by modulating the PYY/PYY<sub>3&#x2013;36</sub> ratios. Therefore, it remains to be explored how possible effects on PYY cleavage contribute to metabolic effects of DPP-IV inhibitors in diabetic patients.</p>
    <p>Moreover, DPP-IV is not only a protease for substrates relevant to energy homeostasis, but it also has a range of additional functions (Boonacker and Van Noorden <xref ref-type="bibr" rid="CR4">2003</xref>). Therefore, it is considered to be a moonlighting protein. As a protease, it has several other substrates, and it also acts as a receptor and costimulatory protein in the immune system. In this regard, CD26 is considered to be an important regulator of T-cell function (Reinhold et al. <xref ref-type="bibr" rid="CR15">2008</xref>). These pleiotropic effects of DPP-IV or CD26 lead to numerous potential uses of its inhibitors other than type 2 diabetes including inflammatory diseases (Ohnuma et al. <xref ref-type="bibr" rid="CR13">2006</xref>; Reinhold et al. <xref ref-type="bibr" rid="CR16">2007</xref>; Thielitz et al. <xref ref-type="bibr" rid="CR20">2008</xref>; Thompson et al. <xref ref-type="bibr" rid="CR21">2007</xref>) and, perhaps, certain types of cancers (Kikkawa et al. <xref ref-type="bibr" rid="CR9">2005</xref>; Thompson et al. <xref ref-type="bibr" rid="CR21">2007</xref>). Some of these effects may manifest as useful secondary actions when being used for the treatment of diabetic patients whereas others may manifest as adverse events. Most of these potential additional effects may not yet have manifested in the currently published diabetes literature, but it appears prudent to keep an eye on them.</p>
  </body>
  <back>
    <ack>
      <title>Open Access</title>
      <p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Batterham</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Cowley</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Small</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dakin</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Wren</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Brynes</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ghatei</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Cone</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Bloom</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Gut hormone PYY3&#x2013;36 physiologically inhibits food intake</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>418</volume>
          <fpage>650</fpage>
          <lpage>654</lpage>
          <pub-id pub-id-type="doi">10.1038/nature00887</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY3&#x2013;36 physiologically inhibits food intake. Nature 418:650&#x2013;654 <pub-id pub-id-type="pmid">12167864</pub-id></citation>
      </ref>
      <ref id="CR2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bischoff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype</article-title>
          <source>Endocrinol</source>
          <year>1998</year>
          <volume>139</volume>
          <fpage>3018</fpage>
          <lpage>3021</lpage>
          <pub-id pub-id-type="doi">10.1210/en.139.6.3018</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bischoff A, Michel MC (1998) Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype. Endocrinol 139:3018&#x2013;3021 </citation>
      </ref>
      <ref id="CR3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boggiano</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Chandler</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Oswald</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Rodgers</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Blundell</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Beattie</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Holch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Schindler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arndt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rudolf</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schoelch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Joost</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Klaus</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Th&#xF6;ne-Reineke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benoit</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Seeley</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Beck-Sickinger</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Koglin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Raun</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Madsen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wulff</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Stidsen</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Birringer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kreuzer</surname>
              <given-names>OJ</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Whitcomb</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Halem</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tayloer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Datta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Culler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ortmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Castaneda</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Tsch&#xF6;p</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>PYY3&#x2013;36 as an anti-obesity drug target</article-title>
          <source>Obesity Rev</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>307</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1467-789X.2005.00218.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Th&#xF6;ne-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Tayloer J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tsch&#xF6;p M (2005) PYY3&#x2013;36 as an anti-obesity drug target. Obesity Rev 6:307&#x2013;322 </citation>
      </ref>
      <ref id="CR4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boonacker</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Noorden</surname>
              <given-names>CJF</given-names>
            </name>
          </person-group>
          <article-title>The multifunctional or moonlighting protein CD26/DPPIV</article-title>
          <source>Eur J Cell Biol</source>
          <year>2003</year>
          <volume>82</volume>
          <fpage>53</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1078/0171-9335-00302</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Boonacker E, Van Noorden CJF (2003) The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82:53&#x2013;73 <pub-id pub-id-type="pmid">12647932</pub-id></citation>
      </ref>
      <ref id="CR5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Combettes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kargar</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Newly approved and promising antidiabetic agents</article-title>
          <source>Therapie</source>
          <year>2008</year>
          <volume>62</volume>
          <fpage>293</fpage>
          <lpage>310</lpage>
        </citation>
        <citation citation-type="display-unstructured">Combettes M, Kargar C (2008) Newly approved and promising antidiabetic agents. Therapie 62:293&#x2013;310 <pub-id pub-id-type="pmid">17983555</pub-id></citation>
      </ref>
      <ref id="CR6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Degen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Oesch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Graf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ketterer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Drewe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Beglinger</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Effect of peptide YY3&#x2013;36 on food intake in humans</article-title>
          <source>Gastroenterology</source>
          <year>2005</year>
          <volume>129</volume>
          <fpage>1430</fpage>
          <lpage>1436</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2005.09.001</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C (2005) Effect of peptide YY3&#x2013;36 on food intake in humans. Gastroenterology 129:1430&#x2013;1436 <pub-id pub-id-type="pmid">16285944</pub-id></citation>
      </ref>
      <ref id="CR7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermansen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kipnes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Faurik</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Khatami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin</article-title>
          <source>Diabetes, Obesity &amp; Metab</source>
          <year>2007</year>
          <volume>9</volume>
          <fpage>733</fpage>
          <lpage>745</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1463-1326.2007.00744.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hermansen K, Kipnes M, Luo E, Faurik D, Khatami H, Stein P (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity &amp; Metab 9:733&#x2013;745 </citation>
      </ref>
      <ref id="CR8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>ThidayMyint</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Neyra</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Kuwayama</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Effects of peripheral administration of PYY3&#x2013;36 on feed intake and plasma acyl-ghrelin levels in pigs</article-title>
          <source>J Endocrinol</source>
          <year>2006</year>
          <volume>191</volume>
          <fpage>113</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="doi">10.1677/joe.1.06855</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ito T, ThidayMyint H, Murata T, Inoue H, Neyra RM, Kuwayama H (2006) Effects of peripheral administration of PYY3&#x2013;36 on feed intake and plasma acyl-ghrelin levels in pigs. J Endocrinol 191:113&#x2013;119 <pub-id pub-id-type="pmid">17065394</pub-id></citation>
      </ref>
      <ref id="CR9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kikkawa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kajiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nomura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mizutani</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Dipeptidyl peptidase IV in tumor progression</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2005</year>
          <volume>1751</volume>
          <fpage>45</fpage>
          <lpage>51</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S (2005) Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751:45&#x2013;51 <pub-id pub-id-type="pmid">16054016</pub-id></citation>
      </ref>
      <ref id="CR10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Date</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shimbara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hanada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Toshinai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Niijima</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Furuya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Inomata</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Osuye</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakazato</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The role of the vagal nerve in peripheral PYY3&#x2013;36-induced feeding reduction in rats</article-title>
          <source>Endocrinol</source>
          <year>2005</year>
          <volume>146</volume>
          <fpage>2369</fpage>
          <lpage>2375</lpage>
          <pub-id pub-id-type="doi">10.1210/en.2004-1266</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya M, Inomata N, Osuye K, Nakazato M (2005) The role of the vagal nerve in peripheral PYY3&#x2013;36-induced feeding reduction in rats. Endocrinol 146:2369&#x2013;2375 </citation>
      </ref>
      <ref id="CR11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mentlein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dahms</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Grandt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kr&#xFC;ger</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV</article-title>
          <source>Regul Pept</source>
          <year>1993</year>
          <volume>49</volume>
          <fpage>133</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1016/0167-0115(93)90435-B</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mentlein R, Dahms P, Grandt D, Kr&#xFC;ger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133&#x2013;144 <pub-id pub-id-type="pmid">7907802</pub-id></citation>
      </ref>
      <ref id="CR12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michel</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Beck-Sickinger</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Doods</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Larhammar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Quirion</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Westfall</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors</article-title>
          <source>Pharmacol Rev</source>
          <year>1998</year>
          <volume>50</volume>
          <fpage>143</fpage>
          <lpage>150</lpage>
        </citation>
        <citation citation-type="display-unstructured">Michel MC, Beck-Sickinger AG, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz TW, Westfall TC (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol Rev 50:143&#x2013;150 <pub-id pub-id-type="pmid">9549761</pub-id></citation>
      </ref>
      <ref id="CR13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohnuma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Uchiyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamochi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hosono</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dang</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Morimoto</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>T-cell activation via CD26 and caveolin-1 in rheumatoid synovium</article-title>
          <source>Mod Rheumatol</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>3</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1007/s10165-005-0452-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ohnuma K, Inoue H, Uchiyama M, Yamochi T, Hosono O, Dang NH, Morimoto C (2006) T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 16:3&#x2013;13 <pub-id pub-id-type="pmid">16622717</pub-id></citation>
      </ref>
      <ref id="CR14">
        <citation citation-type="other">Parkinson JRC, Dhillo WS, Small CJ, Chaudhri OB, Bewick GA, Pritchard I, Moore S, Ghatei MA, Bloom SR (2008) PYY<sub>3&#x2013;36</sub> injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones. Am J Physiol (in press)</citation>
      </ref>
      <ref id="CR15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reinhold</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bank</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>T&#xE4;ger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ansorge</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wrenger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thielitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lendeckel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Faust</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neubert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brocke</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis</article-title>
          <source>Front Biosci</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>2356</fpage>
          <lpage>2363</lpage>
          <pub-id pub-id-type="doi">10.2741/2849</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Reinhold D, Bank U, T&#xE4;ger M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S (2008) DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci 13:2356&#x2013;2363 <pub-id pub-id-type="pmid">17981717</pub-id></citation>
      </ref>
      <ref id="CR16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reinhold</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Biton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Goihl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pieper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lendeckel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Faust</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neubert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bank</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>T&#xE4;ger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ansorge</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brocke</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2007</year>
          <volume>1110</volume>
          <fpage>402</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="doi">10.1196/annals.1423.042</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Reinhold D, Biton A, Goihl A, Pieper S, Lendeckel U, Faust J, Neubert K, Bank U, T&#xE4;ger M, Ansorge S, Brocke S (2007) Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann N Y Acad Sci 1110:402&#x2013;409 <pub-id pub-id-type="pmid">17911455</pub-id></citation>
      </ref>
      <ref id="CR17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sloth</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Davidsen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Holst</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Flint</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Astrup</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Effect of subcutaneous injections of PYY1&#x2013;36 and PYY3&#x2013;36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males</article-title>
          <source>Am J Physiol</source>
          <year>2007</year>
          <volume>293</volume>
          <fpage>E604</fpage>
          <lpage>E609</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A (2007a) Effect of subcutaneous injections of PYY1&#x2013;36 and PYY3&#x2013;36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol 293:E604&#x2013;E609 </citation>
      </ref>
      <ref id="CR18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sloth</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Holst</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Flint</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gregersen</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Astrup</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Effects of PYY1&#x2013;36 and PYY3&#x2013;36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects</article-title>
          <source>Am J Physiol</source>
          <year>2007</year>
          <volume>292</volume>
          <fpage>E1062</fpage>
          <lpage>E1068</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A (2007b) Effects of PYY1&#x2013;36 and PYY3&#x2013;36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol 292:E1062&#x2013;E1068 </citation>
      </ref>
      <ref id="CR19">
        <citation citation-type="other">Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M (2008) Pharmacological profile of ASP8497, a novel, selective and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg&#x2019;s Arch Pharmacol (in press). DOI 10.1007/s00210-008-0277-8</citation>
      </ref>
      <ref id="CR20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thielitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ansorge</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bank</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Tager</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wrenger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gollnick</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Reinhold</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin disease</article-title>
          <source>Front Biosci</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>2364</fpage>
          <lpage>2375</lpage>
          <pub-id pub-id-type="doi">10.2741/2850</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thielitz A, Ansorge S, Bank U, Tager M, Wrenger S, Gollnick H, Reinhold D (2008) The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin disease. Front Biosci 13:2364&#x2013;2375 <pub-id pub-id-type="pmid">17981718</pub-id></citation>
      </ref>
      <ref id="CR21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ohnuma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Abe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Morimoto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dang</surname>
              <given-names>NH</given-names>
            </name>
          </person-group>
          <article-title>CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders</article-title>
          <source>Mini Rev Med Chem</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>253</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.2174/138955707780059853</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH (2007) CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 7:253&#x2013;273 <pub-id pub-id-type="pmid">17346218</pub-id></citation>
      </ref>
      <ref id="CR22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Utzschneider</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Udaysankar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gerchman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Marcovina</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Ligueros-Saylan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Holst</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Deacon</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>The dipeptidyl peptidase-4 inhibitor vildagliptin improves b-cell function and insulin sensitivity in subjects with impaired fasting glucose</article-title>
          <source>Diabetes Care</source>
          <year>2008</year>
          <volume>31</volume>
          <fpage>108</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="doi">10.2337/dc07-1441</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Utzschneider KM, Tong J, Montgomery B, Udaysankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan M, Foley JE, Holst JJ, Deacon CF, Kahn SE (2008) The dipeptidyl peptidase-4 inhibitor vildagliptin improves &#x3B2;-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31:108&#x2013;113 <pub-id pub-id-type="pmid">17909087</pub-id></citation>
      </ref>
      <ref id="CR23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoek</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Heijboer</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Voshol</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Havekes</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Romijn</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Corssmit</surname>
              <given-names>EPM</given-names>
            </name>
            <name>
              <surname>Pijl</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Chronic PYY3&#x2013;36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice</article-title>
          <source>Am J Physiol</source>
          <year>2006</year>
          <volume>292</volume>
          <fpage>E238</fpage>
          <lpage>E245</lpage>
        </citation>
        <citation citation-type="display-unstructured">van den Hoek AM, Heijboer AC, Voshol PJ, Havekes LM, Romijn JA, Corssmit EPM, Pijl H (2006) Chronic PYY3&#x2013;36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol 292:E238&#x2013;E245 </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>